Li Yaohui, Wang Zewei, Jiang Wenbin, Zeng Han, Liu Zhaopei, Lin Zhiyuan, Qu Yang, Xiong Ying, Wang Jiajun, Chang Yuan, Bai Qi, Wang Yiwei, Liu Li, Zhu Yu, Xu Le, Xia Yu, Guo Jianming, Xu Jiejie
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Oncoimmunology. 2020 Oct 27;9(1):1838141. doi: 10.1080/2162402X.2020.1838141.
Tumor necrosis receptor super family (TNFRSF) plays an important role in regulating the function of CD8 T cells. In this study, we explored the clinical significance and immune profile of TNFRSF9 CD8 T cells in clear cell renal cell carcinoma (ccRCC).
The infiltration of immune cells was determined by immunohistochemistry in ZS cohort from our hospital and their prognostic value was further determined by Cox regression. Functional status of CD8 T cells in ccRCC was determined by flow cytometry in 29 fresh tumor samples. In silico analysis on a TCGA cohort and other datasets was performed to further demonstrate our findings.
High TNFRSF9 CD8 T cells infiltration was associated with inferior overall survival in ZS cohort ( = .0016) and TCGA-KIRC cohort ( = .018). TNFRSF9 CD8 T cells expressed higher exhaustion markers (PD-1, TIM-3, CTLA-4, and TIGIT), and effector markers (IFN-γ, GZMB, CD107a, and Ki-67), than their TNFRSF9 negative counterparts. In silico analysis indicated the expression of TNFRSF9 was significantly correlated with IFNG, GZMK, MKI-67, PDCD1, HAVCR2, TIGIT, and CTLA-4 in CD8 T cells. However, higher TNFRSF9 signature was correlated with larger tumor size shrinkage ( = .003) and better progression-free survival ( = .012) in patients treated with nivolumab but not everolimus.
TNFRSF9 CD8 T cells, which possessed both exhaustion and effector phenotype, were identified as an adverse prognosticator in ccRCC. These cells enrichment was associated with better immunotherapy response which indicated these cells potentially be crucial in immunotherapy.
肿瘤坏死因子受体超家族(TNFRSF)在调节CD8 T细胞功能中起重要作用。在本研究中,我们探讨了TNFRSF9 CD8 T细胞在透明细胞肾细胞癌(ccRCC)中的临床意义和免疫特征。
通过免疫组化确定我院ZS队列中免疫细胞的浸润情况,并通过Cox回归进一步确定其预后价值。通过流式细胞术检测29份新鲜肿瘤样本中ccRCC患者CD8 T细胞的功能状态。对TCGA队列和其他数据集进行了计算机分析,以进一步证实我们的发现。
ZS队列(P = 0.0016)和TCGA-KIRC队列(P = 0.018)中,TNFRSF9 CD8 T细胞高浸润与较差的总生存期相关。与TNFRSF9阴性的CD8 T细胞相比,TNFRSF9 CD8 T细胞表达更高的耗竭标志物(PD-1、TIM-3、CTLA-4和TIGIT)和效应标志物(IFN-γ、GZMB、CD107a和Ki-67)。计算机分析表明,TNFRSF9的表达与CD8 T细胞中的IFNG、GZMK、MKI-67、PDCD1、HAVCR2、TIGIT和CTLA-4显著相关。然而,在接受纳武单抗治疗而非依维莫司治疗的患者中,较高的TNFRSF9特征与更大的肿瘤大小缩小(P = 0.003)和更好的无进展生存期(P = 0.012)相关。
TNFRSF9 CD8 T细胞具有耗竭和效应表型,被确定为ccRCC的不良预后指标。这些细胞的富集与更好的免疫治疗反应相关,表明这些细胞在免疫治疗中可能至关重要。